Table 3 The proportion of stage IV cases... | American Society of Hematology

Table 3

The proportion of stage IV cases with each risk factor by marrow status identified by PET or BMB

Risk factor	BM involvement identified by PET-CT (%)		BM involvement identified by biopsy (%)
Risk factor	PET⁺	PET^–	BMB⁺	BMB^–
Age, >60 y	13/33 (39)	6/11 (55)	5/14 (36)	14/30 (47)
IPI 3-5	26/33 (79)	10/11 (91)	12/14 (86)	24/30 (80)
HIV-positive	7/33 (21)	2/11 (18)	4/14 (29)	5/30 (17)
≥4 organ sites* of extranodal disease	8/33 (24)	3/11 (27)	6/14 (43)	5/30 (17)
High-risk gene rearrangement†	6/17‡ (35)	2/7‡ (28)	6/9‡ (67)	2/15‡ (13)

Risk factor	BM involvement identified by PET-CT (%)		BM involvement identified by biopsy (%)
Risk factor	PET⁺	PET^–	BMB⁺	BMB^–
Age, >60 y	13/33 (39)	6/11 (55)	5/14 (36)	14/30 (47)
IPI 3-5	26/33 (79)	10/11 (91)	12/14 (86)	24/30 (80)
HIV-positive	7/33 (21)	2/11 (18)	4/14 (29)	5/30 (17)
≥4 organ sites* of extranodal disease	8/33 (24)	3/11 (27)	6/14 (43)	5/30 (17)
High-risk gene rearrangement†	6/17‡ (35)	2/7‡ (28)	6/9‡ (67)	2/15‡ (13)

At least 3 separate extranodal disease sites, plus bone marrow involvement.

IGH/MYC and double hit (IGH/MYC+IGH/BCL2) rearrangements.

Lymphoma genetics screening only became routine during the second half of the study period.